Researchers have reported better long-term results of coronary artery bypass grafting (CABG) than of percutaneous coronary ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted the company’s IND application for Gemini. This announcement allows the Company to ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of ...